Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
Open Access
- 25 July 2017
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (12) , 1793-1797
Abstract
The range of glycated haemoglobin ( HbA1c ) responses and characteristics associated with above‐average response to exenatide twice daily and once weekly were examined. Data were pooled from 8 exenatide‐twice‐daily and 5 exenatide‐once‐weekly studies. A baseline HbA1c ‐corrected measure of change in HbA1c after 24 weeks identified high, average and low responses. Multiple linear regression and multivariate generalized estimating equation models identified factors associated with high response. Among 2355 participants (exenatide twice daily, n = 1414; exenatide once weekly, n = 941), baseline HbA1c correlated with change in HbA1c ( P < .0001). Across baseline HbA1c levels, the 25th to 75th percentile of HbA1c change ranged from −0.3% to −3.2% with exenatide twice daily and from −0.5% to −3.6% with exenatide once weekly. Asian ethnicity and older age were significantly associated with high response to exenatide twice daily; no factors were significantly associated with response to exenatide once weekly. These data provide clinically useful information for estimating the likelihood that, depending on baseline HbA1c , an individual can achieve HbA1c goals. The association between Asian ethnicity, age and high response to exenatide twice daily may relate to the specific effects of exenatide twice daily on postprandial glucose.Keywords
Funding Information
- AstraZeneca
This publication has 20 references indexed in Scilit:
- Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experienceDiabetes, Metabolic Syndrome and Obesity, 2013
- Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitusJournal of Diabetes Investigation, 2012
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeksJournal of Diabetes Investigation, 2010
- Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year studyDiabetes, Obesity and Metabolism, 2010
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort DatabaseDiabetes Care, 2010
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 DiabetesThe American Journal of Medicine, 2010
- Relationship of baseline HbA1c and efficacy of current glucose‐lowering therapies: a meta‐analysis of randomized clinical trialsDiabetic Medicine, 2010
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group studyClinical Therapeutics, 2008